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Mixed Connective Tissue Disease (MCTD) is a rare complex systemic autoimmune
disease (SAD) characterized by the presence of increased levels of anti-U1
ribonucleoprotein autoantibodies and signs and symptoms that resemble other SADs
such as systemic sclerosis (SSc), rheumatoid arthritis (RA), and systemic lupus
erythematosus (SLE). Due to its low prevalence, this disease has been very poorly studied
at the molecular level. We performed for the first time an epigenome-wide association
study interrogating DNA methylation data obtained with the Infinium MethylationEPIC
array from whole blood samples in 31 patients diagnosed with MCTD and 255 healthy
subjects. We observed a pervasive hypomethylation involving 170 genes enriched for
immune-related function such as those involved in type I interferon signaling pathways or
in negative regulation of viral genome replication. We mostly identified epigenetic signals
at genes previously implicated in other SADs, for example MX1, PARP9, DDX60, or
IFI44L, for which we also observed that MCTD patients exhibit higher DNA methylation
variability compared with controls, suggesting that these sites might be involved
in plastic immune responses that are relevant to the disease. Through methylation
quantitative trait locus (meQTL) analysis we identified widespread local genetic effects
influencing DNA methylation variability at MCTD-associated sites. Interestingly, for IRF7,
IFI44 genes, and the HLA region we have evidence that they could be exerting a
genetic risk on MCTD mediated through DNA methylation changes. Comparison of
MCTD-associated epigenome with patients diagnosed with SLE, or Sjögren’s Syndrome,
reveals a common interferon-related epigenetic signature, however we find substantial
epigenetic differences when compared with patients diagnosed with rheumatoid arthritis
and systemic sclerosis. Furthermore, we show that MCTD-associated CpGs are potential
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epigenetic biomarkers with high diagnostic value. Our study serves to reveal new
genes and pathways involved in MCTD, to illustrate the important role of epigenetic
modifications in MCTD pathology, in mediating the interaction between different genetic
and environmental MCTD risk factors, and as potential biomarkers of SADs.
Keywords: mixed connective tissue disease, systemic autoimmunity, genome-wide DNAmethylation, epigenetics,
interferon, meQTL, biomarker
INTRODUCTION
Mixed connective tissue disease(MCTD) is a complex rare
systemic autoimmune disease (SAD) characterized by the
presence of high levels of anti-U1 ribonucleoprotein (anti-
RNP) autoantibodies and a mixture of signs and symptoms that
resemble other systemic autoimmune diseases (SADs). MCDT
was first recognized through overlapping features with systemic
lupus erythematosus (SLE), systemic sclerosis (SSc), myositis,
and rheumatoid arthritis (RA) (1). But its similarity to these
diseases has led to controversies around its existence as a separate
entity, as an overlap syndrome or as a predecessor to any one of
each of the other connective tissue diseases (CTD). In fact, a small
percentage of patients diagnosed with MCTD evolve into SLE or
SSc (2, 3). Nowadays, MCTD is considered a disease on its own.
Since MCTD was described, four proposals for classification
criteria have been published (4–6), but none of them is
totally accepted by the medical community, challenging the
comparison between studies (4). Currently, MCTD is diagnosed
by the presence of anti-RNP antibodies, Raynaud’s phenomenon,
diffuse hand edema (“puffy hands”), and at least two of the
following symptoms: arthritis, myositis, leukopenia, esophageal
dysmotility, pleuritis, pericarditis, interstitial lung disease, or
pulmonary hypertension (4). However, none of these features
are unique of MCTD. Its clinical heterogeneity together with
its similarities with other CTD, particularly with SSc make its
diagnosis difficult. In addition, its prevalence is lower than other
SADs, affecting mainly females around their 40 s. For the reasons
described above, this disease has been very poorly studied at the
molecular level.
As with other SADs, in the development of MCTD genetic
and environmental factors combined are involved. However, its
etiology is currently unknown. On the one hand, no evidence
of potential environmental factors exist for MCTD (4). On
the other, the role of genetics in its pathogenesis is unclear.
The importance of the genes in MCTD is manifested by the
presence of a family history and its comorbidity with other SADs
(7). However, few genetic studies have been performed in this
diseasemainly due to the difficulty in obtaining large case-control
cohorts, hence only HLA-DRB1∗04:01 has been confirmed as a
genetic risk factor for MCTD (8, 9).
Epigenetic modifications are defined as those structural
adaptation of chromosomal regions that can register, signal,
and perpetuate through cell division altered cellular activity and
transcriptional states without altering DNA sequence. Epigenetic
modifications can mediate individuals’ immune responses to
genetic risk factors as well as to various external and internal
changing conditions. Their study is important for the immune
system as they determine the transcriptional landscapes of cells
during cell differentiation and activation of immune cells (10).
The most extensively studied epigenetic mark in population-
based genome-wide association studies is DNA methylation
(DNAm). Alteration in the DNAm patterns has been postulated
as an important cause in the development of autoimmunity (11).
In the last decade, epigenome-wide association studies (EWAS)
have provided insights into SADs, identifying new loci and
pathways implicated in their pathogenesis, in the development
of specific phenotypic manifestations and in the response to
treatment (12). For instance, the global hypomethylation of
interferon (IFN)-inducible genes is well-described and confirmed
in different immune cell types of patients with SLE and Sjögren’s
syndrome (SjS) (12, 13). This epigenetic interferon signature
seems to occur early in the hematopoietic process, remaining
during periods of disease flares, providing a mechanism to
explain type I IFN hyper-responsiveness in SLE (13).
The aim of this study is to discover novel epigenetic changes
associated with MCTD, to investigate how different genetic and
immune conditions can interact in shaping the variability of
DNAm at MCTD-associated sites, and finally to give insight
into differences between the MCTD- epigenome and other SAD
pathologies. For this purpose, we performed the first epigenome-
wide association study interrogating DNAm levels obtained with
the newest Infinium MethylationEPIC array from whole blood
samples of 31 patients diagnosed with MCTD and 255 healthy
subjects and integrate our results with genetic data, clinical
records and with data obtained from other SAD such as SLE, SjS,
RA, and SSc.
RESULTS
Genome-Wide DNA Methylation Patterns
Associated With MCTD
We explored DNAm patterns associated with MCTD
using the Infinium MethylationEPIC BeadChip comparing
methylation levels between 31 MCTD patients and 255
healthy controls reaching 776,283 autosomic CpG sites (see
Supplementary Table 1 for demographic characteristics of
the study sample). For that, we interrogated how DNAm
levels at each CpG site change depending on MCTD status
while correcting for age, sex, batch effects and blood cellular
composition by means of a linear regression model. The
observed P-value distribution for all association tested against
the expected null distribution shows no genomic inflation
(Supplementary Figure 1). In total, we observed 182 differential
methylated CpGs sites (MCTD-DMS), located within 70
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differentially methylated genes (MCTD-DMG) (Figure 1A,
Supplementary Table 2), that passed our Bonferroni-corrected
threshold for multiple testing (P < 6.4 × 10−08). Table 1 shows
the results for the top 30 MCTD-DMS. In the majority of
MCTD-DMS (94%), we found lower DNAm levels in patients
compared with controls, supporting the observations of massive
hypomethylation previously described in other related SADs
(14–19) (Figure 1B). Among those MCTD-DMGs showing the
largest differences in DNAm levels between patients and controls
(|1β| > 0.2) we find genes and regions such as IFI44L, MX1,
PARP9/DTX3L, EPSTI1, IFIT3, DDX60, IFIT1, and NLRC5, all of
them lying within interferon-inducible genes. In an independent
sample of 21 MCTD cases and 103 controls for which we had
DNAm information based on 450K bead array, we could test
again 100 of these MC20TD-DMS (55%) and we successfully
replicated 99 of them (99%, P < 0.05) (Supplementary Table 2).
Differences in DNAm for those CpGs located within the X-
chromosome were analyzed separately only in females in order
to avoid sex-biased results in a total of 217 samples and 17,530
probes. At a Bonferroni-corrected significance level (P < 2.9 ×
10−06) we found no evidence of differential methylation (data
not shown).
We next performed a genome-wide search for CpG-
sites showing differences in DNAm variability across MCTD
patients and controls. We called these sites as MCTD-
associated variable methylated sites (MCTD-VMS). In total,
we observed 97 MCTD-VMS, located within 50 variable
methylated genes (MCTD-VMG) (Supplementary Table 3) that
passed our Bonferroni-corrected threshold for multiple testing
(P < 6.4 × 10−08). Table 2 shows results for the top 30
MCTD-VMS. For every MCTD-VMS we found higher DNAm
variability in MCTD patients compared with controls. MCTD-
VMS could represent CpG sites with altered and plastic
DNAm profiles underlying different pathological molecular
processes. In our replication sample we could test 53 of
these MCTD-VMS (54%) and we successfully replicated 40 of
them (75%, P < 0.05) (Supplementary Table 3). We found
an overlap of 83 MCTD-VMS with MCTD-DMS, indicating
that a large fraction of differentially methylated sites associated
with MCTD also show increased variability. Figure 1C shows
DNAm variability across MCTD and controls for the top 5
associated DMS.
To identify common functional characteristics of MCTD-
associated epigenetic alterations, we performed gene ontology
(GO) analysis of biological processes including all differentially
methylated genes. Functional enrichment analysis revealed that
type I interferon signaling pathway (GO:0060337), cellular
response to type I interferon (GO:0071357), and interferon-
gamma-mediated signaling pathway (GO:0060333) were the
most significantly enriched GO terms (adjusted P < 7 × 10−19).
Other immune-related functions related to the innate immunity
such as cytokine-mediated signaling pathway (GO:0019221),
negative regulation of viral life cycle (GO:1903901) and negative
regulation of viral genome replication (GO:0045071) were among
the top significant GO terms (adjusted P < 7 × 10−15)
(Supplementary Table 4).
Treatment Effects on MCTD-Associated
Epigenetic Signals
DNAm levels fluctuate when exposed to environmental
exposures such as the intake of drugs (20). MCTD patients often
receive one ormore treatments throughout their lives to diminish
disease symptoms. At the time of blood sampling, MCTD
patients included in this study were mostly exposed to therapies
such as steroids, antimalarials and/or immunosuppressants
(Supplementary Table 1). To investigate the influence of this
exposure on our findings, we first explored whether or not
DNAm levels at MCTD-DMS were still associated with MCTD
diagnosis when treatments are included as covariates in the
linear model. All previously described MCTD-DMS remained
significantly associated after treatment correction at least at a
significance level as low as P < 0.007 (Supplementary Table 2),
moreover we observed a high correlation between the effects of
the disease on DNAm levels and the significance level obtained
from themodel with and without treatment correction (Pearson’s
r > 0.95, P < 2.2e−16) (Figure 2A), which suggests that the
MCTD epigenetic signature is not fully explained or significantly
influenced by therapy.
In order to further explore whether or not there exists DNAm
patterns associated with the disease that are dependent on
specific treatments, we stratified the MCTD patients according
to treatment and compared the results obtained between the
untreated and the treated group (Figures 2B–D). For example,
when stratifying the associations by immunosuppressive
treatment, we observed a high correlation (Pearson’s r = 0.94)
between effect sizes obtained in the untreated and treated groups,
indicating that the genome-wide epigenetic signature does not
depend on the therapy. However, we observed a tendency of
effect sizes being generally larger in the untreated group than
in the treated, which indicates that the epigenetic state of those
individuals under immunosuppressive treatment resembles
more that of the healthy population (Figure 2B). The same
is seen for those patients under steroid therapy (Figure 2C).
Interestingly, an opposite pattern is observed for the group using
antimalarials whose epigenetic profile differs more from the
untreated group (Figure 2D). Finally, we individually searched
for treatment-specific effects among MCTD-DMS by selecting
those associations that were significant in one group (after
correction for multiple testing) but with little evidence for
association in the other (P > 0.01) (Supplementary Tables 5,
6). Due to our limited sample size in the stratified analyses
these results are likely to be influenced by the little power,
we only report as treatment-specific effects those that could
be replicated in our independent sample. We found robust
immunosuppressive-specific epigenetic effects at the genes
PARP14, SPATS2L, DDX58, OAS2, PLSCR1, HLA-F, LGALS3B
(Table 3). Examples for these treatment-specific effects are
exemplified in Figures 2E–H in which DNAm levels are depicted
in the healthy group, in all MCTD patients, in those untreated
subjects, and in the treated group for which we can see a reversal
of DNAm levels toward the control group. Interestingly, for
SPATS2L and OAS2 genes, we can see how MCTD patients
exhibit an hypermethylation compared with controls, as well as
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FIGURE 1 | Results from epigenome-wide association study (EWAS) in mixed connective tissue disease. (A) Manhattan plot showing the EWAS results. P-values are
represented on the –log10 scale in the y-axis. The genomic position for each CpG tested is represented in the x-axis. Discontinuous blue line represents the
genome-wide significance threshold (P < 6.4 × 10−08). The top 10 associations are labeled with gene names. (B) Volcano plot of the EWAS results. P-values are
represented on the –log10 scale in the y-axis. The effect size and direction of obtained in EWAS result for each CpG site is depicted in the x-axis. Red dots represent
significant associations. The top 10 associations are labeled with gene names. (C) Boxplot representing the top five differentially methylated CpG-sites in cases and
healthy controls. DNAm levels are presented in the y-axis. Horizontal line is the boxplot corresponds to the median DNAm levels for each group.
the treated subjects compared with the untreated ones, which
is the opposite trend for what is seen in most MCTD-DMS.
Our results indicate that some epigenetic associations are, at
least partially, modified by therapy, and suggest that targeting
specific-epigenetic alterations could be a potential molecular
mechanism to revert the disease.
Genetic Drivers of MCTD-Associated
Differential Methylation
Other than environmental and stochastic factors, genetic
variation is also an important contributor in shaping DNAm
levels across the genome, as described in several recent genetic
DNAm quantitative trait loci (meQTL) studies (20–23). In
order to gain insight into the genetic control of the MCTD-
associated epigenetic signals, we performed cis-meQTL analyses
to detect genetic variants located closely to MCTD-DMS (no
further than 1Mb) that influence DNAm irrespectively of disease
status. For that, we included 259 subjects (29 MCTD and 230
CTRL) for which both EPIC DNAm and genetic data were
available. The observed P-value distribution for all cpg-SNP
associations tested against the expected null distribution shows
no genomic inflation and is depicted in Supplementary Figure 2.
At a False Discovery Rate (FDR) < 0.05 we detected 2,077
genetic-epigenetic associations involving 31 MCTD-DMS and
1,806 SNPs, many of which are in high linkage disequilibrium
(LD) (Supplementary Table 7). MCTD-associated cis-meQTLs
are distributed across 21 differentially methylated genes, or
MCTD-DMGs, among which EPST1, VRK2, ADAR, and IRF7
are the genes whose DNAm pattern show the strongest genetic
control. Table 4 shows the top genetic effects for each MCTD-
DMG. In an independent sample of 20 MCTD cases and 96
controls for which we had DNAm information based on 450K
bead array, we could test again 909 of these MCTD-DMS (37%)
sitting along 25 genes, and we successfully replicated meQTLs
for 11 MCTD-DMGs (40%, at a significance level of P < 0.001)
(Supplementary Table 8). These results demonstrate that there is
a widespread effect of local genetic variants onMCTD-associated
DNAm sites.
Intermediary Role of DNA Methylation in
MCTD Genetic Risk
Next, we addressed the question of whether or not SNPs involved
in meQTL do show differences in allele frequencies between
patients and controls and could represent MCTD-associated
genetic variants exerting their genetic risk on the disease through
DNAm changes. For that, we performed genetic association
testing by means of logistic regression analyses in an extended
sample of 89 MCTD and 550 CTRLs for which we had genotypic
data. At a suggestive significance level of P < 0.05, we found 168
genetic variants that are associated both with DNAm levels at 8
CpG sites and show some evidence of being associated with risk
for MCTD, that could potentially impact on MCTD pathology
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TABLE 1 | Top differentially methylated sites in MCTD epigenome-wide analysis.
CpG site Position Gene MCTDmet CTRLmet β P
cg13452062 1:79088559 IFI44L 0.35 0.86 −0.51 2.0 × 10−54
cg22930808 3:122281881 PARP9; DTX3L 0.38 0.72 −0.33 1.4 × 10−42
cg24678928 4:169240829 DDX60 0.58 0.82 −0.24 7.7 × 10−42
cg05696877 1:79088769 IFI44L 0.29 0.69 −0.40 1.1 × 10−41
cg06188083 10:91093005 IFIT3 0.35 0.55 −0.25 8.6 × 10−40
cg08122652 3:122281939 PARP9; DTX3L 0.56 0.82 −0.26 4.4 × 10−38
cg07815522 2:122282157 PARP9; DTX3L 0.44 0.72 −0.29 5.9 × 10−38
cg21549285 21:42799141 MX1 0.43 0.79 −0.36 1.0 × 10−37
cg00959259 3:122281975 PARP9; DTX3L 0.32 0.59 −0.26 2.4 × 10−37
cg22862003 21:42797588 MX1 0.41 0.64 −0.24 1.5 × 10−36
cg03607951 1:79085586 IFI44L 0.26 0.54 −0.25 2.5 × 10−34
cg01028142 2:7004578 CMPK2 0.68 0.87 −0.19 3.6 × 10−34
cg26312951 21:42797847 MX1 0.21 0.37 −0.18 1.6 × 10−33
cg03038262 11:315262 IFITM1 0.41 0.52 −0.15 9.6 × 10−33
cg05552874 10:91153143 IFIT1 0.41 0.67 −0.24 1.8 × 10−32
cg06562969 13:43567153 EPSTI1 0.49 0.63 −0.17 3.5 × 10−32
cg07839457 16:57023022 NLRC5 0.26 0.49 −0.24 6.4 × 10−31
cg25998594 14:24632095 IRF9 0.78 0.87 −0.11 6.7 × 10−31
cg05883128 4:169239131 DDX60 0.37 0.50 −0.16 1.9 × 10−30
cg23570810 11:315102 IFITM1 0.45 0.60 −0.19 1.9 × 10−30
cg06981309 3:146260954 PLSCR1 0.26 0.46 −0.17 8.0 × 10−30
cg13155430 21:42795929 MX1 0.75 0.90 −0.15 3.5 × 10−29
cg21995613 8:144106922 Intergenic 0.65 0.75 −0.12 1.2 × 10−28
cg13304609 1:79085162 IFI44L 0.73 0.85 −0.12 4.5 × 10−28
cg14595557 2:7006786 CMPK2 0.29 0.42 −0.11 1.2 × 10−27
cg10959651 2:7018020 RSAD2 0.14 0.26 −0.12 1.3 × 10−26
cg05475649 15:45007015 B2M 0.43 0.53 −0.15 1.4 × 10−26
cg08888522 2:163172908 IFIH1 0.73 0.87 −0.13 4.4 × 10−26
cg04880620 12:113415945 OAS2 0.46 0.51 −0.07 4.0 × 10−25
cg27537252 15:45006400 B2M 0.32 0.48 −0.20 1.3 × 10−24
MCTDmet represents mean methylation level in MCTD cases.
CTRLmet represents mean methylation level in controls.
β represents DNAm difference between controls and MCTD cases.
P is the P-value obtained in the linear regression model adjusted by age, sex, batch effects, and estimated cell proportions.
Genomic positions are based on the hg19 human reference sequence build (GRCh37).
by changing DNAm levels in a cis-regulating manner, many
of them sitting in the same haplotypic block and influencing
the same CpG site. (Supplementary Table 9). Table 5 shows
the top MCTD-associated SNPs influencing DNAm levels at
MCTD-DMS. To give further support to the robustness of their
associations and their link with autoimmunity, we investigated
if they are also genetically associated with other immune-related
diseases such as SLE, SjS, RA, and SSc for which we also had
available genotypic data. Importantly, genetic variants at IFI44
(rs1051047), the intergenic region at chr18 (rs73936737), and the
HLA-region (rs2251892, rs3130251) gave convincing evidence of
their genetic association with SLE and/or SjS (0.05 > P > 4 ×
10−08) (Table 5, Supplementary Table 9).
As an example of the potential intermediary role of DNm in
MCTD pathology, we illustrate in Figures 3A–F the relationship
between genetic variants, DNAm and MCTD for an intergenic
region in chromosome 18 and for the HLA-F gene. The
presence of the T minor allele (rs2251892) in the HLA-
G and HLA-H region in chromosome 6 is associated with
a decrease in DNAm levels (cg23892836) at the upstream
located HLA-F gene (Figure 3B) and with higher MCTD risk
(Figure 3D). Such relationships support the scenario in which
this risk variant, which is found at higher frequencies in MCTD
patients (Figure 3D), is implicated in the disease by reducing
DNAm levels at this HLA class I histocompatibility antigen
(Figures 3A,B). On the contrary, the presence of the G minor
allele (rs73936737) in the chromosome 18 intergenic region, is
linked with an increase in DNAm nearby and associated with a
lower MCTD risk (Figures 3F–H). This indicates that the genetic
variant could exert its protective role by reducing DNAm levels
at the intergenic region (Figure 3E). These results demonstrate
that MCTD-specific differences in DNAm may be driven by
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TABLE 2 | Top variable methylated sites in MCTD epigenome-wide analysis.
CpG site Position Gene MCTDvar CTRLvar LevTest P
cg01028142 2:7004578 CMPK2 0.172 0.015 223.8 1.0 × 10−37
cg21549285 21:42799141 MX1 0.287 0.053 217.9 5.4 × 10−37
cg08122652 2:122281939 PARP9; DTX3L 0.214 0.033 216.4 8.3 × 10−37
cg24678928 4:169240829 DDX60 0.186 0.033 195.8 3.4 × 10−34
cg07815522 3:122282157 PARP9; DTX3L 0.227 0.042 192.4 9.4 × 10−34
cg08888522 2:163172908 IFIH1 0.141 0.023 186.4 5.6 × 10−33
cg13304609 1:79085162 IFI44L 0.125 0.035 184.9 8.9 × 10−33
cg24298610 21:42796936 MX1 0.090 0.025 179.9 4.1 × 10−32
cg22930808 3:122281881 PARP9; DTX3L 0.236 0.045 174.9 1.9 × 10−31
cg05883128 4:169239131 DDX60 0.151 0.041 169.2 1.1 × 10−30
cg08926253 11:614761 IRF7 0.131 0.040 165.1 4.3 × 10−30
cg13155430 21:42795929 MX1 0.146 0.021 162.8 8.8 × 10−30
cg22862003 21:42797588 MX1 0.180 0.046 160.5 1.8 × 10−29
cg06708931 8:144103857 Intergenic 0.100 0.015 145.7 2.3 × 10−27
cg25998594 14:24632095 IRF9 0.097 0.023 145.6 2.4 × 10−27
cg06033320 8:66750110 PDE7A 0.165 0.066 134.6 9.7 × 10−26
cg12037516 11:614954 IRF7 0.075 0.022 130.5 4.0 × 10−25
cg05552874 10:91153143 IFIT1 0.180 0.054 119.4 1.9 × 10−23
cg03038262 11:315262 IFITM1 0.140 0.057 119.2 2.1 × 10−23
cg01079652 1:79118191 IFI44 0.177 0.034 117.3 4.2 × 10−23
cg22016995 11:614787 IRF7 0.114 0.012 117.2 4.2 × 10−23
cg21995613 8:144106922 Intergenic 0.121 0.047 116.1 6.3 × 10−23
cg12906975 8:144105259 Intergenic 0.066 0.012 108.9 8.5 × 10−22
cg13452062 1:79088559 IFI44L 0.327 0.040 108.9 8.5 × 10−22
cg16400320 8:144105210 Intergenic 0.063 0.019 108.2 1.1 × 10−21
cg11702942 8:144102584 LY6E 0.089 0.034 106.7 1.9 × 10−21
cg25984164 1:174844560 RABGAP1L 0.142 0.065 104.3 4.5 × 10−21
cg14293575 22:18635460 USP18 0.184 0.028 97.0 7.1 × 10−20
cg14864167 8:66751182 PDE7A 0.200 0.073 96.2 9.6 × 10−20
MCTDvar represents DNA methylation variability in MCTD cases measured as its standard deviation.
CTRLvar represents DNA methylation variability in controls measured as its standard deviation.
LevTest represents the test statistic obtained in the Levene’s test.
P is the P value obtained for Levene’s test comparing variance between MCTD cases and controls in DNAm residuals after adjusted by age, sex, batch effects, and estimated
cell proportions.
Genomic positions are based on the hg19 human reference sequence build (GRCh37).
underlying genetic variants, and provide a molecular mechanism
by which genetic polymorphisms can contribute to disease.
Epigenetic Sharing Across Other Systemic
Autoimmune Diseases
MCTD is a SAD that exhibits a high degree of sharing of
symptoms and serology with other SADs making it difficult to
diagnose and treat. Moreover, recent EWAS on other SADs,
such as SjS and SLE, have revealed a common epigenetic
signature at IFN-inducible genes that we also observe in the
blood of MCTD patients (14–17, 19, 24). Here, we explored
to what extent the MCTD-associated epigenetic signals are
distinguishable from those of other related SADs, such as SLE,
SjS, RA, and SSc. For that, we used 234, 206, 217, and 177 samples,
respectively. We first investigated whether or not MCTD-DMS
are also differentially methylated in other SADs when compared
with the healthy population. To illustrate the results of this
cross-diseases comparison, we have represented in a heatmap
the effect sizes obtained for each disease and for 31 CpG-
sites for which we observed an absolute DNAm difference
higher than 0.15 when compared with controls (Figure 4A).
At a Bonferroni-significance level of P < 2.7 × 10−04, we
observed that most MCTD-associated epigenetic sites are also
SLE-DMS (98%) and SjS-DMS (98%), while a much lower
fraction are found to be associated with SSc (20%) or with RA
(15%) (Supplementary Table 10). Indeed, when comparing the
magnitude of the effects of MCTD-epigenetic associations with
those from different diseases, we found the highest effect sizes
correlation between MCTD and SjS models (Pearson’s r = 0.98)
followed by SLE (Pearson’s r =0.97), and a substantially lower
correlation with SSc (Pearson’s r = 0.89) and RA (Pearson’s
r = 0.80), and hence reduced similarities with these effect
sizes (Figure 4B). This pattern was consistent in our replication
sample (Supplementary Figure 3). Interestingly, we observed
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FIGURE 2 | Treatment effects on the MCTD epigenetic associations. (A–D) Effect size correlation plots to compare results from different models. (A) In the x-axis
results from linear models in which the treatments are not included as covariates are depicted. In the y-axis results from linear models in which treatments are included
as covariates are depicted. (B–D) Effect size comparisons for treatment-stratified analyses comparing effect sizes in the treated sample and in the untreated sample.
(E–H) Boxplots for immunosuppressive specific epigenetic signals. DNAm levels are illustrated in controls, MCTD cases, untreated MCTD cases and treated MCTD
cases in different CpG sites.
TABLE 3 | Treatment stratification epigenetic association results for immunosuppressive therapy.
Discovery sample (EPIC) Replication sample (450K)
CpG site Position Gene Treated β (P) Untreated β (P) Treated β (P) Untreated β (P)
cg01721555 3:122401300 PARP14 −0.01 (0.072) −0.03 (4.5 × 10−12) −0.01 (0.208) −0.04 (2.0 × 10−04)
cg03035167 2:201336269 SPATS2L 0.01 (0.238) 0.05 (6.9 × 10−10) 0.02 (0.019) 0.05 (3.0 × 10−06)
cg03848588 9:32525008 DDX58 −0.01 (0.149) −0.04 (4.4 × 10−15) −0.01 (0.043) −0.03 (1.8 × 10−04)
cg07253769 12:113447342 OAS2 0.03 (0.014) 0.07 (4.2 × 10−12) 0.02 (0.171) 0.06 (4.3 × 10−04)
cg18686270 3:146258875 PLSCR1 −0.01 (0.177) −0.04 (4.4 × 10−11) −0.01 (0.396) −0.07 (5.9 × 10−04)
cg23892836 6:29692085 HLA-F −0.04 (0.016) −0.07 (2.6 × 10−10) −0.04 (0.012) −0.07 (4.6 × 10−04)
cg25178683 17:76976267 LGALS3BP −0.02 (0.198) −0.11 (3.6 × 10−16) −0.04 (0.026) −0.07 (5.3 × 10−04)
Treated β (P) represents the DNA methylation differences between treated MCTD cases and controls.
Untreated β (P) represents the DNA methylation differences between untreated MCTD cases and controls.
P represents the P-value obtained from in the linear regression model adjusted by age, sex, batch effects, and estimated cell proportions.
Genomic positions are based on the hg19 human reference sequence build (GRCh37).
that the difference between DNAm levels is usually higher for
MCTD than for SjS and/or SLE when compared with the healthy
population (Figure 4A, Supplementary Table 10).
Finally, we interrogated whether or not there exist significant
DNAm differences between MCTD and every other disease
at the entire set of MCTD-DMS (Supplementary Table 11).
At a Bonferroni-significance level of P < 2.7 × 10−04, we
observed no significant DNAm difference between MCTD
and SLE, while only 1 CpG showed significant differences
in DNAm between MCTD and SjS. However, we detected
a large number of differential methylation sites for RA
and SSc (154 and 137, respectively). Figure 4C shows the
DNAm profile across the different diseases and the healthy
population for the top differentially methylated genes. CpG
cg12037516 (IRF7 gene) showed the largest DNAm difference
between MCTD and SjS patients. CpG cg13452062 (IFI44L
gene) showed the largest DNAm difference between MCTD
and RA patients. And finally, the CpG cg01028142 (CMPK2
gene) showed the largest DNAm difference between MCTD
and SSc.
Our results reveal in first place that MCTD is epigenetically
linked to SLE and SjS, as they all shared a common IFN
epigenetic signature, but that for MCTD a more striking
pattern of DNAm differentiation is observed. We also show that
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TABLE 4 | Best meQTL results per MCTD-DMS.
CpG site CpG position CpG gene SNP Alleles SNP position SNP gene β P
cg12439472 13:43565399 EPSTI1 rs4142312 GA 13:43574986 EPSTI1 −0.167 2.6 × 10−44
cg09858955 2:58135951 VRK2 rs2678900 GT 2:58177683 VRK2 0.056 3.3 × 10−20
cg07878065 18:2641871 Intergenic rs9958281 AG 18:2641809 Intergenic 0.019 1.1 × 10−19
cg03879629 3:46152446 Intergenic rs13085367 CT 3:46172824 Intergenic 0.072 2.7 × 10−18
cg04268125 1:154579384 ADAR rs9616 TA 1:154555733 ADAR 0.060 7.9 × 10−18
cg23892836 6:29692085 HLA-F rs2517910 AC 6:29688501 HLA-F −0.030 4.8 × 10−16
cg17114584 11:613792 IRF7 rs3740648 TG 11:596672 PHRF1 −0.084 4.0 × 10−15
cg00272009 3:122398855 PARP14 rs2668339 CG 3:122392433 PARP14 −0.040 1.1 × 10−14
cg23923934 6:31322914 HLA-B rs1051488 TC 6:31322911 HLA-B −0.039 1.3 × 10−14
cg12331471 2:231282369 SP100 rs12694859 TC 2:231254570 SP140L −0.029 9.2 × 10−14
cg06981309 3:146260954 PLSCR1 rs2738918 CT 3:146257165 PLSCR1 0.039 1.1 × 10−12
cg14864167 8:66751182 PDE7A rs6472232 GT 8:66792632 PDE7A −0.048 1.7 × 10−12
cg12110437 8:144098888 LY6E rs7812819 GA 8:144095249 RP11-273G15.2. −0.046 1.0 × 10−11
cg23352030 20:62198469 PRIC285 rs9784182 GA 20:62263201 Intergenic 0.054 1.0 × 10−11
cg13755924 21:42791937 MX1 rs78554586 AG 21:42808343 MX1 −0.053 1.9 × 10−11
cg14880222 1:79143979 Intergenic rs7524036 AC 1:79158657 Intergenic 0.029 1.0 × 10−10
cg08293824 3:172313318 Intergenic rs234055 GT 3:172310820 RP11-408H1.3 0.038 1.8 × 10−10
cg07839313 19:17514600 BST2 rs12971834 TC 19:17516689 CTD-2521M24.9,/BST2 −0.027 3.8 × 10−10
cg06033320 8:66750110 PDE7A rs6472232 GT 8:66792632 PDE7A −0.034 5.4 × 10−10
cg07596065 22:50984393 Intergenic rs9306547 CT 22:50993225 SYCE3 0.016 8.4 × 10−10
cg12013713 7:139760671 PARP12 rs7805521 AT 7:139761176 PARP12 0.032 7.9 × 10−09
cg09379489 12:12224360 BCL2L14 rs4763773 GA 12:12225613 BCL2L14 −0.024 1.6 × 10−08
cg24603130 18:60253492 ZCCHC2 rs57868717 TC 18:60247316 ZCCHC2 −0.032 2.3 × 10−08
cg16427501 8:145060083 PARP10 rs11136343 GA 8:145058986 PARP10 0.017 4.2 × 10−08
cg26202327 2:233193151 DIS3L2 rs10933388 AT 2:233176366 DIS3L2 −0.035 5.0 × 10−08
cg10734665 15:26107410 ATP10A rs12908995 AG 15:26015194 ATP10A −0.025 7.5 × 10−08
Alleles represents the allele tested in first place followed by the non-tested allele for each SNP.
β represents the DNA methylation change in the addition of one allele tested.
P represents the P-value obtained from the linear regression model adjusted by age, sex, batch effects, estimated cell proportions, disease status and first genetic component.
Genomic positions are based on the hg19 human reference sequence build (GRCh37).
there exist substantial epigenetic differences with RA and SSc,
which indicates that these epigenetic dissimilarities can be of
interest to develop new blood biomarkers that could distinguish
effectively MCTD from other SADs, as it is explored in the
next section.
Diagnostic Utility of MCTD-Associated
Methylation to Differentiate MCTD From
Healthy Populations and Other
Autoimmune Systemic Diseases
Lastly, we wanted to evaluate the diagnostic value of MCTD-
associated epigenetic markers to distinguish MCTD patients
from healthy population, but also from the other 4 distinct
systemic autoimmune related diseases (SLE, SjS, RA, and SSc).
Firstly, we conducted logistic regression and ROC curves
analyses based on DNAm levels at individual CpG sites for
the 31 MCTD-DMS that show the highest DNAm differences
(|1β| > 0.15) between MCTD and healthy subjects. DNAm
status at 10 CpGs sitting in genes PARP9, IFI44L, MX1,
PLSCR1, IFIT1, NLRC5, and DDX60 show high diagnostic
performance to distinguish MCTD from healthy patients (Area
Under Curve (AUC) > 0.90), being the highest cg22930808
at PARP9 gene which exhibited an AUC of 0.94 (Figure 5A,
Supplementary Table 12). We found no CpG that individually
could distinguish proficiently MCTD patients from those
diagnosed with SLE or SjS (AUC < 0.65). However, we found
a good diagnostic value (AUC > 0.80) to discriminate MCTD
from RA and SSc at 17 and 10 CpG sites, respectively, being
the highest cg13452062 at IFI44L for RA (AUC = 0.87) and
cg22930808 at PARP9 gene for SSc (AUC = 0.85). Importantly,
when we added the information of DNAm at the top 10
discriminating CpG sites in the logistic regression as predicting
covariates, we increased our MCTD diagnostic ability reaching
AUC values as high as 0.96 to differentiate from the healthy
population, 0.90 to differentiate from RA patients and 0,88 to
differentiate from SSc (Figure 5B). Notably, we also obtained
a reasonable good performance to discriminate MCTD from
SLE and SjS (AUC = 0.76 and 0.74, respectively), which
surprisingly makes epigenetic biomarkers a very interesting tool
to distinguish between epigenetically resembling diseases as well
(Figure 5B).
Lastly, DNAm levels at IFI44L gene has been previously
described to serve as an effective biomarker to distinguish






























TABLE 5 | Genetic effects of MCTD-meQTLs in MCTD and other related SADs.
CpG site CpG location CpG Gene SNP SNP location SNP Gene Alleles AF meQTL EWAS β (P) MCTD OR (P) SAD (OR,P)
MCTD/CTRL β (P)
cg15331332 chr6:29692111 HLA-F rs3130251 chr6:29629344 MOG CT 0.24/0.15 −0.03 −0.06 1.86 (0.0014) SLE(1.63, 2 x 10−05)
(9.8 x 10−08) (2.9 x 10−08) SjS (1.94, 4 x 10−08)
cg23892836 chr6:29692085 HLA-F rs2251892 chr6:29833128 HLA-H/HLA-G TC 0.43/0.33 −0.02 −0.06 1.59 (0.004) SLE (1.23,0.03)
(8.8 x 10−09) (1.4 x 10−09) SjS (1.53, 2 x 10−05)
cg17114584 chr11:613792 IRF7 rs3740648 chr11:596672 PHRF1 TG 0.14/0.08 −0.08 −0.14 1.98 (0.007) –
(4.0 × 10−15) (1.7 × 10−22)
cg07878065 chr18:2641871 intergenic rs73936737 chr18:2635566 intergenic (chr18) GA 0.15/0.26 0.01 −0.03 0.57 (0.007) SLE (0.75, 0.007)
(9.9 × 10−08) (5.0 × 10−09)
cg14880222 chr1:79143979 intergenic rs1051047 chr1:79129694 IFI44 GA 0.50/0.60 0.03 −0.04 0.40 (0.017) SLE (0.72, 0.05),
(1.7 × 10−09) (4.3 × 10−09) SjS (0.72, 0.06)
cg04268125 chr1:154579384 ADAR rs11264235 chr1:154631081 intergenic (chr1) TC 0.40/0.28 −0.04 −0.2 1.43 (0.036) –
(4.7 × 10−08) (2.0 × 10−23)
cg00272009 chr3:122398855 PARP14 rs16834903 chr3:122379614 intergenic (chr3) AG 0.40/0.36 −0.04 −0.09 1.37 (0.048) –
(5.7 × 10−14) (1.9 × 10−11)
cg26882438 chr3:122399120 PARP14 rs16834903 chr3:122379614 intergenic (chr3) AG 0.40/0.36 −0.03 −0.14 1.37 (0.048) –
(1.7 × 10−10) (2.6 × 10−20)
Alleles represent the allele tested in first place followed by the non-tested allele for each SNP. Tested allele frequency is given in parenthesis.
AF corresponds to the allele frequency of the tested allele in cases and controls.
meQTL β (P) represents the DNAm change in the addition of one tested allele together with the corresponding P value from the linear regression model adjusted by age, sex, batch effects, estimated cell proportions, disease status and
first genetic component.
EWAS β (P) represents DNAm difference between controls and MCTD cases from epigenome-wide association study together with the P value obtained in the linear regression model adjusted by age, sex, batch effects and estimated
cell proportions.
MCTD (OR,P) represents the Odd Ratio obtained from genetic association testing based on logistic regression model adjusted by age, sex, batch effects, estimated cell proportions and first genetic component and its corresponding
P value.
SAD (OR, P) represents the odd ratio and P value obtained for other diseases.
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FIGURE 3 | Intermediary role of DNAm in the genetic risk of MCTD. (A) Summary of relationships between PHRF1-genotype (rs12362352), DNAm at IRF7
(cg17114584), and MCTD. The p-values shown were obtained in the corresponding meQTL, EWAS, or genetic association analyses. (B) G minor allele for
PHRF1-genotype (rs12362352) is associated with a decreased in DNAm at IRF7 gene (cg17114584). (C) DNAm at DNAm at IRF7 gene (cg17114584) shows
decreases DNAm levels in MCTD patients than controls (CTRL). (D) G minor allele for PHRF1-genotype (rs12362352) is associated with increased MCTD risk. (E)
Summary of relationships between HLA-B-genotype (rs2507991), DNAm at HLA-B (cg23923934), and MCTD. (F) A minor allele for HLA-B-genotype (rs2507991) is
associated with an increased in DNAm at HLA-B gene (cg23923934). (G) DNAm at HLA-B gene (cg23923934) shows decreases DNAm levels in MCTD patients than
controls (CTRL). (H) A minor allele for HLA-B-genotype (rs2507991) is associated with decreased MCTD risk.
SLE from the healthy population, as well as from SjS and RA
(25). Here we interrogated the diagnostic utility of DNAm
to differentiate MCTD between the healthy population and
other SADs-related diseases. For that, we evaluated the joined
diagnostic value of 6 IFI44L-MCTD-DMS (cg13452062,
cg05696877, cg03607951, cg13304609, cg17980508, and
cg00458211). Our results show a very high IFI44L discriminating
value to differentiate MCTD between the healthy population,
RA and SSc patients (AUC = 0.97, 0.90, and 0.84, respectively),
but not as good ability to discriminate MCTD from SLE and
SjS patients (AUC < 0.71), as when putting the epigenetic
information from different interferon-related genes together
(Figures 5B,C). These results were highly concordant with
those obtained in our replication independent sample based on
450K data (Supplementary Table 13), which serves to replicate
and/or cross-validate our results and to give robustness to
these findings.
DISCUSSION
This is the first time that MCTD is studied at the molecular, and
particularly at the epigenetic level. We have found widespread
DNAm changes associated withMCTD, the vast majority of them
shows decreased DNAm levels in MCTD patients compared with
healthy subjects in genes that are transcriptionally responsive
to the presence of interferon or involved in type I interferon
pathways. Most of our signals are located in genes that have
been previously reported in EWAS studies to be associated
with other related SADs, such as SLE and SjS in whole blood,
but also in other different fractioned blood cell types (14–
17, 19, 24). However, this is it the first time, to be best of
our knowledge, that the epigenetic state of an autoimmune
disease is interrogated at the resolution of > 700,000 CpG sites
in the genome (Infinium MethylationEPIC array). Functional
enrichment analysis based on EPIC methylation data confirm
the epigenetic IFN signature and expands the list of CpG-
associated with autoimmune diseases. Our study also reveals
that for most MCTD-associated epigenetic signals, an increase in
DNAm variability is observed. This disease-associated increased
DNAm variability has been previously seen for other immune-
related conditions and could reflect different scenarios (19, 26,
27). Firstly, it could be the result of the plastic nature of the
activated immune cells involved in the disease (28). Secondly,
increases in DNAm variability can underlie the contribution of
many different molecular processes to MCTD etiology, which
could be reflected as well in the high heterogeneity observed
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FIGURE 4 | Epigenetic patterns of MCTD-epigenetic signatures in other related systemic autoimmune diseases. (A) Heatmap representing the absolute effect
magnitude of epigenetic associations for different systemic autoimmune diseases at those MCTD-DMS showing absolute effect sizes higher than 0.15. Each column
represents one disease, each row represents the absolute effect size obtained for the corresponding disease when compared with healthy subjects. (B) Correlation
plots comparing the effect sizes obtained in the MCTD epigenetic association results (in the y-axis) with those obtained for other systemic autoimmune diseases
(x-axis). (C) Boxplots representing the top differentially methylated CpG-sites between MCTD cases and other SADs. DNAm levels are illustrated in controls, MCTD,
SLE, SjS, RA, and SSc.
at the level of clinical manifestations, as it is also the case for
other SADs.
The MCTD patients involved in this study were mostly
under steroids, antimalarial or immunosuppressive medication
at the time of blood sampling. We show that adjusting our
analyses for treatment did not change significantly our results,
which indicates that our findings are not mainly driven by
treatment effects. However, we see a general trend toward a
more pronounced DNAm difference in the untreated group and
intermediate DNAm levels in the treated group compared with
healthy subjects. Indeed, a number of CpG sites, for example
those in genes such as OAS2, PLSCR1, SPATS2L, and DDX58,
could only be detected as significantly associated with MCTD
in the untreated group. These results were largely confirmed in
our replication sample and suggest that at least some epigenetic
associations are modified by therapy. These findings open a
gate to study how targeting the epigenetic state at IFN-related
genes could be a potential molecular drug mechanism to revert
the disease.
A number of previous studies have suggested that DNAm
could be a mediator of genetic risk in disease (19, 21, 29), which
provides a functional mechanism to link genetic variation with
disease. By integrating genetic and DNAm data we conducted
meQTL analyses and observed strong evidence of cis genetic
regulation of DNAm levels at a large fraction of MCTD-DMS.
To date, there is no genome-wide association study published
for MCTD. The fact that MCTD is a rare complex disease
exhibiting a mixture of heterogeneous symptoms that resembles
other SADs has challenged the recruitment of large enough
samples to conduct GWAS studies. However, here we could
explore whether genetic variants involved in MCTD-meQTLs do
show some evidence of being genetically associated with MCTD
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FIGURE 5 | Diagnostic value of MCTD-associated epigenetic signals. (A) ROC curves for PARP9 DNAm (cg22930808) to discriminate patients with MCTD from the
healthy population (CTRL), SLE, SjS, RA, and SSc. (B) ROC curves for the top 10 CpG-sites discriminating MCTD from CTRLs (cg22930808, cg03607951,
cg13452062, cg22862003, cg06981309, cg05552874, cg07839457, cg24678928, cg00959259, cg05696877) to discriminate patients with MCTD from the healthy
population (CTRL), SLE, SjS, RA, and SSc. (C) ROC curves of IFI44L DNAm. (cg13452062, cg05696877, cg03607951, cg13304609, cg17980508, cg00458211) to
discriminate patients with MCTD from healthy population (CTRL), SLE, SjS, RA, and SSc. AUC, Area under the curve.
and/or with other related SADs. Interestingly, we reveal that
genetic variants at 5 loci are both associated with MCTD risk
and with DNAm levels at genes IFI44, PHRF1, in the HLA
region and in two other intergenic regions. Although these
results need further confirmation in larger and independent
samples, our findings in other SADs indicate that these genetic
variants could potentially impact MCTD pathology by changing
DNAm levels, as it has been previously suggested for other
diseases and phenotypes (19, 21, 29). Future studies including
larger samples and applying causal inference statistical methods,
such as Mendelian randomization, would further confirm the
intermediary role of DNAm in MCTD genetic risk, as it has been
demonstrated for other pathologies.
This is also the first time that DNAm levels at five different
SADs is compared in the same study. Our results indicate,
firstly, that a high degree of blood epigenetic sharing is found
between MCTD, SjS, and SLE patients, but not between MCTD
and SSc or RA as it could have been expected from the
disease commonalities and diagnostic criteria. The interferon
epigenetic signature observed for MCTD has been widely
reported in the EWAS literature for SLE and SjS in whole
blood, but also in other different fractionated blood cell types
(14–19, 24). Intriguingly, we show here that for MCTD a
more profound epigenetic differentiation is observed between
cases and controls, which could imply a molecular mechanisms
underlying a more profound molecular changes. If these
changes relate to clinical manifestations or symptoms would
require further investigation.
Finally, we illustrate for the first time the great diagnostic
potential of whole blood DNAm levels to discriminate MCTD
patients. The results of our study show that DNAm levels at
many individual MCTD-DMS in whole blood present very high
diagnostic value to differentiate MCTD patients from healthy
controls and perform reasonably well to discriminate MCTD
from RA and SSc patients. DNAm levels at PARP9 and IFI44L
genes exhibit the highest discrimination ability, which is in line
with findings from previous studies for other SADs and in other
blood fractionated cell types (25, 30). Moreover, we show that
adding the information of the top 10 discriminating CpG-sites
boosts the diagnostic value and makes epigenetic biomarkers a
potential tool to discriminate MCTD from SLE and SjS patients
as well, even if they show a similar epigenetic signature. Given
our promising results, and the fact that whole blood DNAm
changes are easily measured from readily accessible peripheral
blood samples, we conclude that epigenetic based biomarkers




Samples included in this study were obtained from the European
PRECISESADS project [URL: http://www.precisesads.eu/] (31),
a multi-center cross-sectional clinical study, with recruitment
performed between December 2014 and October 2017 at
19 institutions in 9 countries (Austria, Belgium, France,
Germany, Hungary, Italy, Portugal, Spain, and Switzerland,
see Supplementary Note for a relation of centers involved
in recruitment). Patients included in this study were aged 18
years or older, and diagnosed as having one of the following
SADs: RA, SSc, SjS, SLE, and/or MCTD. Each patient was
diagnosed according to the prevailing international classification
criteria established for each of these diseases (6, 32–34). Patients
that meet diagnostic criteria for more than one SADs were
excluded from PRECISESADs project. Healthy individuals,
i.e., not having any history of autoimmune or infectious
diseases, were included as controls, and matched to cases to
the extent possible, in gender, age and clinical center of origin.
At the time of blood sampling, clinical and demographic
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information was obtained for every subject including
treatment assessment.
A consensual protocol and informed consent was approved
for by local ethics committees of each participating clinical
center. All subjects provided written informed consent according
to the declaration of Helsinki. For this work, we included patients
for whom there was available DNA methylation data and/or
genotypic information (see Supplementary Table 1).
Genotyping and Imputation
Genomic DNA from whole blood was obtained by standard
methods. All samples were genotyped using HumanCore−12-
v1-0-B, InfiniumCoreExome-24v1-2, and InfiniumCoreExome-
24v1-3 (Illumina, San Diego, CA, USA). Quality control (QC)
was performed using PLINK v1.90b3.39 (35). A total of
213,234 variants passed our filtering criteria when including all
subjects from PRECISESADs projects. We used the FRAPPE
software that use single-nucleotide polymorphisms to estimate
the global ancestry of each individual. To do this, an independent
set of 2,706 genetic markers which exhibit substantially
different frequencies between different populations, i.e., ancestry
informativemarkers (AMs), were used. Also, all 2,504 individuals
from the 1,000 Genomes Project (1000G) were included in the
estimation of the ancestry as reference panel of the five main
global populations (Africa, Europe, American, East Asian, and
South Asian).
Genetic markers were removed following this criteria: (i)
call rate < 90%, (ii) significant differential missingness between
cases and controls (P-value < 1 × 10−4), and/or (iii) significant
deviation from Hardy-Weinberg equilibrium (P-value < 0.01
in controls and P-value < 1 × 10−4 in cases). Samples
were excluded from the study following this criteria: (i)
call rate < 98% and also a high heterozygosity rate, i.e.,
6 standard deviations from the centroid; (ii) duplicated or
related individuals were identified using identity-by-descent
criteria with REAP (36), (iii) a kinship coefficient < 0.25, (iv)
clinical gender data did not match genotypic data, and finally,
(v) <55% European ancestry.
Inference methods based on linkage disequilibrium structure
were used in order to increase the number of genetic markers.
Imputation was performed using the Michigan Imputation
Server [URL: https://imputationserver.sph.umich.edu/index.
html] (37) and Haplotype Reference Consortium (HRC)
as reference panel [URL: http://www.haplotype-reference-
consortium.org/] (38) and using a rsq cutoff to filter the imputed
genotypes of 0.7. Imputed variants were also filtered according
to the protocol described above.
Genome-Wide DNA Methylation Profiling
After DNA extraction from whole peripheral blood and
bisulfite conversion, the genome for each sample was amplified,
fragmented and hybridized to the corresponding Illumina arrays
according to the manufacturer’s protocol. The QC of samples,
probes, and the normalization of the data were performed using
the meffil R software following the developers’ guidelines (39).
Samples were excluded based on the detection p-value criteria
> 99%, poor bisulfite conversion based on control dashboard
check, sex mismatches according to failed chromosome X and Y
clustering, and failure to match genotypic information. Probes
were filtered out based on detection p-value > 0.01 in > 95%
of samples. Additionally, all probes located at the X and Y
chromosomes were separated to avoid gender bias. Probes with
genetic variants at their CpG sites with a minor allele frequencies
higher than 0.05 and those that map to multiple genomic regions
were also excluded following the instructions of recent works that
evaluate the Illumina Methylation EPIC BeadChip microarray
(40). After QC steps, we obtained information on 776,398
probes for samples profiled using the InfiniumMethylation EPIC
BeadChip (Illumina, San Diego, CA, USA). Additionally, we
obtained DNAm data that were profiled using the Infinium
Methylation 450K BeadChip (Illumina, San Diego, CA, USA), for
which we obtained trustable information on 433,337 probes.
The raw methylation beta values were background corrected
and normalized using the functional normalization. DNAm was
measured as a beta value ranging from 0 to 1. Zero represents
an unmethylated state (0% molecules methylated at a particular
sites) while 1 represents a fully methylated state (100% molecules
methylated).We also estimated the cellular composition of whole
blood from the DNAm profiles using the Houseman method
and the blood gse35069 as a cell reference panel (41). Estimated
proportions for neutrophils, monocytes, B lymphocytes, CD4+
lymphocytes, CD8+ lymphocytes, and natural killer (NK)
cells were used as covariates for subsequent association
analyses. For these procedures we used again the meffil
R-package (39).
Identification of MCTD-Associated
Genome-Wide DNA Methylation Patterns
In order to maximize our findings, we separated our samples
accordingly to the platform used to profile DNAm. As a discovery
sample we included all subjects with DNAm data based on
the Infinium Methylation EPIC BeadChip, which comprised
31 subjects diagnosed with MCTD and 255 healthy controls
(CTRL). As a replication sample, we included 21 MCTD patients
and 124 healthy controls for which we had DNAm data based
on the Infinium Methylation 450K BeadChip. Most of the
probes included in the 450K array (∼90%) are also included
in the EPIC array. Epidemiological and clinical features of the
samples included in the discovery and the replication samples are
summarized in Supplementary Table 1. Firstly, we performed
epigenome-wide association analysis (EWAS) to identifyMCTD-
associated differential methylated positions (MCTD-DMS) along
the genome. For every CpG in our discovery sample we evaluated
the effect of being diagnosed with MCTD on DNAm using
a linear regression model corrected by age, sex, batch effects
and estimated cell proportions. We also searched for CpG-sites
showing DNAm variance differences between MCTD patients
and healthy samples and called these as MCTD-associated
variable methylated CpG-sites (MCTD-VMS). For that, we first
residualized DNAm levels correcting for all covariates in a linear
regression model. Then, we searched for variance differences
in DNAm residuals between cases and controls by applying a
Levene’s test that accounts for mean differences. A Bonferroni
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correction was used to declare genome-wide significance (P <
6.25× 10−8) and to identify MCTD-DMS andMCTD-VMS. For
each MCTD-DMS and MCTD-VMS the mean and the variance
was calculated in MCTD patients and CTRL. The same analyses
and models were used in the replication sample to evaluate the
robustness of significant associations in an independent cohort.
We established as replicated MCTD-DMS and MCTD-VMS as
those showing consistent effect direction and P < 0.05.
In order to investigate the influence of treatment effects in
our results, we also run EWAS adjusted the linear regression
model by variables representing whether or not individuals were
under specific treatments at the time of blood sampling. We
only included those treatments that were prescribed in more
than three patients, which are steroids (N = 12), antimalarial
(N = 13), and/or immunosuppressive drugs (N = 9) (see
Supplementary Table 1). Furthermore, we perform stratified
analyses by treatment with the aim to identify treatment-specific
effects at MCTD-DMS. For that we run the linear models
separately in treated and untreated samples and look for those
CpG sites that are significant after Bonferroni correction in one
group (P < 2.7 × 10−04) but with little evidence of association
in the other (P > 0.01). In order to give robustness to treatment
specific effects, we performed the same analyses in our replication
sample. All statistical analyses were performed using R (v3.4.2)
[URL: http://www.R-project.org/].
Functional Enrichment
Significant MCTD-DMS were annotated to genes and gene
locations according to annotation files provided by Illumina,
from which we obtained a list of unique differentially methylated
genes. The online tool of Enrichr program was used to perform
gene set enrichment analysis based on gene ontology (GO)
terms (42).
Methylation Quantitative Trait Loci
(meQTL) Analysis
In order to find cis-genetic variation affecting DNAm levels at
MCTD-DMS, meQTL analysis was performed. Linear regression
models were applied to evaluate the effect of all SNPs sitting
closer than 1Mb to the evaluated CpG site, on DNAm
levels using the Matrix eQTL R software (43). The models
were corrected for sex, age, batch effects, cellular proportions,
disease status and the first genetic principal component. Only
common SNPs with a MAF > 0.05 were included in the
analyses. We discovered meQTLs in a sample that comprised
259 subjects for which we had both EPIC DNAm data and
genotypic information. We used a FDR < 0.05 to correct for
multiple testing. We replicated our findings in a sample that
comprised 116 subjects for which we had both 450K data and
genotypic information.
Genetic Associations
Genetic association case-control analyses were conducted
using PLINK v1.9 (35). Logistic regressions under the
additive model were conducted to interrogate the association
between genetic variants involved in MCTD-meQTLs
and SAD diagnosis. For that, we compared the allele
frequencies of 428 SLE, 400 SSc, 395 SjS, 380 RA, 103
PAPS, and 89 MCTD patients samples vs. 570 controls.
We show none or little evidence for genetic stratification
as detected by genomic control coefficient (GC) (1.20 <




We used linear regression models to find differentially
methylated CpG-sites associated with other SADs for
which we had information on DNAm EPIC data. We
included 234 SLE, 206 SjS, 217 RA, and 177 SSc patients
and the same linear models than previously explained
(Supplementary Table 1). The effect sizes obtained for each
disease were compared with that obtained for MCTD by
means of Pearson’s correlation. We searched for significant
DNAm differences between MCTD and the other SADs by
performing cases vs. cases analyses in a linear regression
model framework that included the same covariates as
previously explained.
Binary Prediction Analysis and ROC
Evaluation
The diagnostic utility of all MCTD-DMS was evaluated by
performing logistic regression analyses and calculating the
AUC curve in both our discovery and replication sample
using the pROC R package. We performed logistic regression
models to find out how well epigenetic markers differentiate
MCTD from the healthy population and also from every
other SADs included in this study. The covariates used in
the logistic models were the same as previously explained for
linear models.
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